Inactive Instrument

Analyst Reco. NuVasive, Inc.

Equities

NUVA

US6707041058

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Barclays Adjusts Price Target on NuVasive to $58 From $56, Maintains Overweight Rating	23-08-04	MT
Truist Securities Adjusts Price Target on NuVasive to $51 From $48, Maintains Hold Rating	23-07-19	MT
Morgan Stanley Adjusts Price Target on NuVasive to $40 From $43, Keeps Equalweight Rating	23-05-31	MT
Barclays Adjusts Price Target on NuVasive to $56 From $53, Maintains Overweight Rating	23-05-12	MT
Morgan Stanley Adjusts Price Target on NuVasive to $43 From $44.50, Maintains Equal-Weight Rating	23-05-11	MT
Morgan Stanley Raises NuVasive's Price Target to $44.50 From $44, Maintains Equalweight Rating	23-02-23	MT
Barclays Raises NuVasive's Price Target to $53 From $52, Maintains Overweight Rating	23-02-23	MT
Jefferies Raises NuVasive's Price Target to $44 From $40, Maintains Hold Rating	23-02-23	MT
JPMorgan Raises NuVasive's Price Target to $45 From $38, Maintains Neutral Rating	23-02-23	MT
RBC Boosts Price Target on NuVasive to $58 From $52, Citing Deal Valuation, Maintains Outperform Rating	23-02-13	MT
Truist Securities Downgrades NuVasive to Hold From Buy, Price Target is $52.50	23-02-10	MT
Citigroup Downgrades NuVasive to Neutral From Buy, Adjusts Price Target to $52 From $63	23-02-10	MT
Wells Fargo Downgrades NuVasive to Equal-Weight Rating From Overweight, Adjusts Price Target to $57.72 From $47	23-02-10	MT
Piper Sandler Downgrades NuVasive to Neutral From Overweight	23-02-09	MT
Truist Securities Adjusts Price Target on NuVasive to $51 From $48, Maintains Buy Rating	23-01-31	MT
Needham Downgrades NuVasive to Hold From Buy	23-01-06	MT
Cowen Cuts Price Target on NuVasive to $50 From $65, Keeps Outperform Rating	22-11-10	MT
Wells Fargo Cuts Price Target on NuVasive to $47 From $62, Affirms Overweight Rating	22-11-10	MT
Piper Sandler Lowers Price Target on NuVasive to $50 From $60, Reiterates Overweight Rating	22-11-10	MT
Morgan Stanley Adjusts Price Target on NuVasive to $44 From $48, Maintains Equalweight Rating	22-11-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. NuVasive, Inc.

Equities

NUVA

US6707041058

Analyst Reco.

Filters